Netarsudil as an Adjunctive Therapy: Efficacy and Factors Contributing to a Favorable IOP-Lowering Effect
Table 6
Adverse effects.
Variable, N (%)
Overall N = 2361
Nonresponder N = 401
Initial responder N = 651
Long-term responder N = 731
Robust long-term responder N = 411
Super responder N = 171
value2
Problem with adherence
22 (9.3)
6 (15)
6 (9.2)
4 (5.5)
5 (12)
1 (5.9)
0.49
Conjunctival hyperemia
90 (38)
13 (32)
26 (40)
27 (37)
16 (39)
8 (47)
0.87
Blurred vision
50 (21)
5 (12)
17 (26)
17 (23)
8 (20)
3 (18)
0.53
Tearing
40 (17)
3 (7.5)
6 (9.2)
22 (30)
8 (20)
1 (5.9)
0.003
Itching
19 (8.1)
2 (5.0)
5 (7.7)
8 (11)
3 (7.3)
1 (5.9)
0.83
Pain
20 (8.5)
2 (5.0)
3 (4.6)
6 (8.2)
5 (12)
4 (24)
0.11
Irritation
30 (13)
4 (10)
5 (7.7)
12 (16)
8 (20)
1 (5.9)
0.28
Burning
9 (3.8)
1 (2.5)
2 (3.1)
3 (4.1)
3 (7.3)
0.67
Dry eye
28 (12)
5 (12)
4 (6.2)
8 (11)
9 (22)
2 (12)
0.19
Headache
11 (4.7)
3 (7.5)
2 (3.1)
5 (6.8)
1 (2.4)
0.53
Eyelid redness
15 (6.4)
3 (7.5)
2 (3.1)
6 (8.2)
3 (7.3)
1 (5.9)
0.78
Eyelid edema
12 (5.1)
4 (10)
1 (1.5)
5 (6.8)
2 (4.9)
0.28
1Mean (SD); (min-max); median for numerical variables; (% missing), or frequency (%); (% missing) for categorical variables. Subjects may have more than one adverse event; therefore, the number of observations is greater than the number of reported subjects. 25-sample test for equality of proportions without continuity correction.
